Roche’s Hemlibra shows benefit in Phase III hemophilia A trial

Roche has reported the initial analysis data from the Phase III HAVEN 7 clinical trial where its bispecific factor IXa-directed and factor X-directed antibody Hemlibra (emicizumab) offered benefit in infants with severe hemophilia A without factor VIII inhibitors.